TY - CHAP M1 - Book, Section TI - Aminoglycosides & Spectinomycin A1 - Beauduy, Camille E. A1 - Winston, Lisa G. A2 - Katzung, Bertram G. A2 - Vanderah, Todd W. Y1 - 2021 N1 - T2 - Basic & Clinical Pharmacology, 15e AB - CASE STUDYA 45-year-old man with no significant medical history was admitted to the intensive care unit (ICU) 10 days ago after suffering third-degree burns over 40% of his body*. He had been relatively stable until the last 24 hours. Now, he is febrile (39.5°C [103.1°F]), and his white blood cell count has risen from 8500 to 20,000/mm3. He has also had an episode of hypotension (86/50 mmHg) that responded to a fluid bolus. Blood cultures were obtained at the time of his fever, and results are pending. The ICU attending physician is concerned about a bloodstream infection and decides to treat with empiric combination therapy directed against Pseudomonas aeruginosa. The combination therapy includes tobramycin. The patient weighs 70 kg (154 lb) and has an estimated creatinine clearance of 90 mL/min. How should tobramycin be dosed using once-daily and conventional dosing strategies? How should each regimen be monitored for efficacy and toxicity? SN - PB - McGraw-Hill CY - New York, NY Y2 - 2024/03/29 UR - accessmedicine.mhmedical.com/content.aspx?aid=1176469090 ER -